Latest Breaking News On - Rare pediatric disease priority review voucher - Page 1 : vimarsana.com

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesAdam mostafaExchange commissionHercules capital incHead of corporate patient affairsPharmaceuticals nasdaqDrug administrationCompany contactCapital infusionPriority review voucherExisting loanRare pediatric disease priority review voucherHercules capitalChief financial officerRare pediatric diseasePrivate securities litigation reform act

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results And Provides Corporate Updates

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results And Provides Corporate Updates
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesPaula raganAmerican society of hematologyPharmaceuticals nasdaqDevelopment rd expensesDrug administrationClinical immunology societyEuropean medicines agencyChief executive officerRare pediatric disease priority review voucherKey anticipated upcoming milestonesAmerican societyCash equivalentsRestricted cashShort term marketable securitiesPriority review voucher

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesPaula raganHead of corporate patient affairsEuropean medicines agencyExchange commissionAmerican society of hematologyClinical immunology societyDrug administrationDevelopment rd expensesPharmaceuticals reports firstPharmaceuticals nasdaqCompany contactReports first quarterProvides corporateChief executive officerRare pediatric disease priority review voucher

FDA Approves X4 Pharmaceuticals Mavorixafor As First Therapy For Rare Immunodeficiency Disorder - X4 Pharmaceuticals (NASDAQ:XFOR)

FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare immunodeficiency disorder. Potential sales forecasted at $54.6M in 2024, rising to $450.9M by 2027.

Pharmaceuticals inc xforxolremdiWhy avenue therapeuticsStock is fallingRare pediatric disease priority review voucherBrookline capital marketsGoing on with sofi technologies stock

X4 Pharmaceuticals Gets FDA Approval for Xolremdi Capsules

By Chris Wack X4 Pharmaceuticals said that the Food and Drug Administration approved Xolremdi capsules for use in patients 12 years of age and older with WHIM syndrome to increase the number.

Chris wackDrug administrationBreakthrough therapy designationNew drug applicationPriority reviewRare pediatric disease priority review voucherDow jones